Summary of Strata Critical Medical 2025 Investor Day Company Overview - **Company**: Strata Critical Medical (NasdaqCM:BLDE) - **Focus**: Organ transplant logistics and critical services, with a recent diversification into cardiac care through the acquisition of Keystone Perfusion [1][3][4] Industry Insights - **Market Need**: Over 100,000 Americans are on the transplant waitlist, with 13 dying daily due to organ shortages. Nearly 50,000 lives were saved through transplants last year [11][12] - **Regulatory Changes**: Evolving donor allocation methodologies are improving organ distribution efficiency, moving from geographic proximity to acuity-based systems [12][14] - **Growth in Donation After Circulatory Death (DCD)**: DCD has quadrupled in the last seven years, with a 20% compound annual growth rate. Strata's technology, normothermic regional perfusion (NRP), is used in about 40% of DCD cases [15][16] Business Model and Strategy - **End-to-End Solution**: Strata offers a comprehensive service from organ recovery to logistics, making it the only full-stack organ recovery platform in the U.S. [5][10] - **Logistics Efficiency**: Locally based surgical recovery teams and aircraft reduce costs and improve response times, addressing the issue of "dry runs" where medical teams arrive to find organs are not recoverable [7][8] - **Acquisition Strategy**: Strata plans to deploy approximately $200 million over the next four years to acquire established businesses in the transplant ecosystem, which could add $25 million in EBITDA [19][21] Financial Outlook - **EBITDA Growth**: The company aims to double its adjusted EBITDA over the next four years based on conservative assumptions, not accounting for potential regulatory changes or increased transplant growth [18] - **Market Share**: Currently holds a 30% share in air logistics and 15% in ground logistics, with significant opportunities for growth through new customer acquisition and expanding ground hub networks [53][55] Key Services and Innovations - **Logistics Services**: Strata provides air and ground logistics, including Next Flight Out and hand carry solutions for kidneys, enhancing service offerings [46][55] - **Safety Standards**: Strata emphasizes safety in operations, exceeding FAA requirements and ensuring reliable service for organ transport [51] Competitive Advantages - **National Scale**: Strata's extensive network of aircraft and ground vehicles allows for efficient logistics management, positioning the company to capture more market share [44][60] - **Customer-Centric Approach**: The company operates on an open-source platform, allowing flexibility in service offerings and fostering strong relationships with transplant centers and OPOs [9][10] Conclusion - Strata Critical Medical is well-positioned to capitalize on the growing organ transplant market through its comprehensive service offerings, strategic acquisitions, and commitment to safety and efficiency. The company is focused on increasing transplant volumes and improving patient outcomes while maintaining a strong financial outlook.